Knowledgebase

In a significant achievement for the field of radionuclide production, a dedicated team consisting of scientists of NRG|PALLAS and Future Chemistry, has successfully completed the SAT for their state-of-the-art, custom made Lu-177 no carrier added (n.c.a.) preparative High Performance Liquid Chromatography (prep-HPLC) system.

The market for lutetium-177 is expected to grow significantly in the coming years. There are many products in the clinical pipeline that use lutetium-177 as radioactive substance, and we are seeing new, up-and-coming therapies. A promising agent is lutetium-177 PSMA, which acts on the prostate-specific membrane antigen and is used in the treatment of metastasised prostate cancer. In addition to prostate carcinomas, other cancers could be treated with the isotope lutetium-177 in the future. Prof. Hendrikse of Amsterdam UMC, VUmc location, foresees expanding possibilities for patient treatment despite some issues related to market availability.

Medical isotope offers great perspective for the effective treatment of various cancer indications with limited side effects